Study #2021-0513
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy and Cellular Kinetics /Pharmacodynamics of ALLO-647and ALLO-605, an Anti-BCMA Allogenic CAR T Cell Therapy in Patients with Relapsed /Refractory Multiple Myeloma
MD Anderson Study Status
Enrolling
Treatment Agent
ALLO-647, Fludarabine, Cyclophosphamide
Description
The purpose of the ALLO-605-201 study is to assess the safety, efficacy, and cell kinetics of ALLO605 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.
Information and next steps
Disease:
Relapsed/Refractory Multiple Myeloma
Study phase:
I/II
Physician name:
Krina Patel
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.